A18 U GOT THE LOOK: DRUGS, TOXINS, GENES AND RISK ASSESSMENT IN PULMONARY HYPERTENSION: Improved Right Ventricular Chamber Size And Contractility After Upfront Combination Therapy With Ambrisentan And Tadalfil In Scleroderma-Associated Pulmonary Arterial Hypertension

In a study of treatment naive SSc-PAH patients (ATPAHSS Trial), initial upfront therapy with a endothelin receptor antagonist (ambrisentan) and phosphodiesterase inhibitor (tadalafil) and demonstrated improvement in hemodynamics and functional status. Echocardiographic analysis included standard ass...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Mercurio, V, Mukherjee, M, Tedford, R, Zamanian, R T, Khair, R, Sato, T, Minai, O, Torres, F, Girgis, R E, Chin, K, Damico, R L, Kolb, T M, Mathai, S, Hassoun, P M
Format: Article
Language:English
Subjects:
Combination therapy
Hypertension
Scleroderma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a study of treatment naive SSc-PAH patients (ATPAHSS Trial), initial upfront therapy with a endothelin receptor antagonist (ambrisentan) and phosphodiesterase inhibitor (tadalafil) and demonstrated improvement in hemodynamics and functional status. Echocardiographic analysis included standard assessment of RV chamber size and function using conventional measures of tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), and tissue Doppler derived S' velocity; and novel RV longitudinal systolic speckle tracking strain (RVLSS) of the basal, mid and apical RV free wall. BASELINE 36 WEEKS p value NORMAL VALUES Age, y 59 ± 10 Female sex, n (%) 21 (91.3) Race White/Black/Other, n 20/2/1 WHO functional class I/II/III/IV, n 0/8/15/0 1/12/10/0
ISSN:1073-449X
1535-4970